Tracer library / [68Ga]DOTA-r-a-ABA-iodoCPCR4
[68Ga]DOTA-r-a-ABA-iodoCPCR4
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- PET
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated CPCR4-based cyclic pentapeptide (CXCR4-targeting ligand)
- Target / mechanism
- CXCR4 receptor PMID 32724470
- Clinical application
- CXCR4-targeted imaging/therapy studied preclinically in Daudi (human B cell lymphoma) xenograft model PMID 32724470
- Theranostic pair
- [177Lu]Lu-DOTA-r-a-ABA-iodoCPCR4
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | — | DOTA-r-a-ABA-iodoCPCR4 | 32724470 2020 Theranostics All peptides and their respective natGa-, natLu-, natY- and natBi- complexes were synthesized in analogy to previously published protocols |
Need this precursor?We can point you to suppliers for [68Ga]DOTA-r-a-ABA-iodoCPCR4, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 32724470. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 32724470: 'DOTA-r-a-ABA-iodoCPCR4 (entry 14)'. Stage set/updated at stage 23 from PMID 32724470: 'will be further evaluated in preclinical and clinical CXCR4-targeted dosimetry and RLT studies.'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Ga-68 is a positron emitter used only for PET imaging. Linked articles: PMID 32724470.